Literature DB >> 9521940

Three-year follow-up of vaccine response in extremely preterm infants.

R Khalak1, M E Pichichero, C T D'Angio.   

Abstract

OBJECTIVE: To assess whether the adequate antibody response observed in former extremely premature infants after the primary series of immunizations is sustained after the first booster vaccines. SUBJECTS AND METHODS: Sixteen former extremely premature (<29 weeks, <1000 g at birth) and 17 former full-term (>37 weeks) infants had sera obtained for antibody titer measurement at 3 to 4 years of age. All had received the primary series and first booster vaccines for diphtheria, pertussis, tetanus, polio, and Haemophilus influenzae type b. Twelve preterm and 14 full-term children had completed the hepatitis B vaccine series.
RESULTS: At 3 to 4 years of age, former preterm and full-term children had similar geometric mean titer (GMT) values of antibodies to tetanus, diphtheria, and pertussis. Preterm children had a lower GMT value of Haemophilus polyribosylribitol phosphate (PRP) antibody than did full-term children (0.99 vs 3.06 microg/mL). Fifty percent of preterm and 88% of full-term children had PRP antibody >1.0 microg/mL; 100% of preterm and 94% of full-term children had anti-PRP titers >0.15 microg/mL. GMT values of neutralizing antibodies to polio serotypes 1 and 2 were similar, with 94% to 100% of both groups above protective levels (>/=1:8). The difference in GMT values of polio serotype 3 approached significance (29 vs 73); fewer preterm children had protective titer values (75% vs 100%). Among children vaccinated against hepatitis B, 75% of preterm and 71% of full-term children were protected (10 mIU/mL).
CONCLUSIONS: Preterm children immunized at the recommended chronological ages displayed antibody responses similar to those for full-term children for most immunizing antigens. Responses to PRP and polio serotype 3 were less robust than those of full-term children.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9521940     DOI: 10.1542/peds.101.4.597

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  8 in total

Review 1.  Immunisation of premature infants.

Authors:  J Bonhoeffer; C-A Siegrist; P T Heath
Journal:  Arch Dis Child       Date:  2006-11       Impact factor: 3.791

2.  Plasma cell and serum antibody responses to influenza vaccine in preterm and full-term infants.

Authors:  Carl T D'Angio; Claire P Wyman; Ravi S Misra; Jessica L Halliley; Hongyue Wang; Julianne E Hunn; Caitlin M Fallone; F Eun-Hyung Lee
Journal:  Vaccine       Date:  2017-08-12       Impact factor: 3.641

3.  Immunoreactivity of intact virions of human immunodeficiency virus type 1 (HIV-1) reveals the existence of fewer HIV-1 immunotypes than genotypes.

Authors:  P N Nyambi; A Nádas; H A Mbah; S Burda; C Williams; M K Gorny; S Zolla-Pazner
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

Review 4.  Active immunization of premature and low birth-weight infants: a review of immunogenicity, efficacy, and tolerability.

Authors:  Carl T D'Angio
Journal:  Paediatr Drugs       Date:  2007       Impact factor: 3.022

5.  Hib vaccination in infants born prematurely.

Authors:  P T Heath; R Booy; J McVernon; J Bowen-Morris; H Griffiths; M P E Slack; A C Moloney; M E Ramsay; E R Moxon
Journal:  Arch Dis Child       Date:  2003-03       Impact factor: 3.791

6.  Weight-based policy of hepatitis B vaccination in very low birth weight infants in Taiwan: a retrospective cross-sectional study.

Authors:  Chien-Yi Chen; Huey-Ling Chen; Hung-Chieh Chou; Po-Nien Tsao; Wu-Shiun Hsieh; Mei-Hwei Chang
Journal:  PLoS One       Date:  2014-03-17       Impact factor: 3.240

Review 7.  Immunization of preterm infants: current evidence and future strategies to individualized approaches.

Authors:  Mats Ingmar Fortmann; Johannes Dirks; Sybelle Goedicke-Fritz; Johannes Liese; Michael Zemlin; Henner Morbach; Christoph Härtel
Journal:  Semin Immunopathol       Date:  2022-08-03       Impact factor: 11.759

8.  Heptavalent pneumococcal conjugate vaccine immunogenicity in very-low-birth-weight, premature infants.

Authors:  Carl T D'Angio; Roy J Heyne; T Michael O'Shea; Robert L Schelonka; Seetha Shankaran; Shahnaz Duara; Ronald N Goldberg; Barbara J Stoll; Krisa P Van Meurs; Betty R Vohr; Abhik Das; Lei Li; Robert L Burton; Betty Hastings; Dale L Phelps; Pablo J Sanchez; Waldemar A Carlo; David K Stevenson; Rosemary D Higgins
Journal:  Pediatr Infect Dis J       Date:  2010-07       Impact factor: 2.129

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.